Targeting regulators of RNA methylation have also shown promise in preclinical models, which are effective against AML, as exemplified by FB23 and FB23-2 (small-molecule inhibitors) of the m6A eraser FTO (Huang et al., 2019). The gene discussed is FTO; the disease is acute myeloid leukemia.